Pay in 4 interest-free payments of $5.05 Learn more
Ships within 48 hours · Estimated delivery Sep 24 - Sep 29
Study participants We identified all adult (aged 20 years) patients with NAFLD and type 2 diabetes who had newly started treatment with non-insulin glucose-lowering drugs (metformin, GLP-1RAs, SGLT2 inhibitors, sulfonylureas, meglitinides, thiazolidinediones, acarbose or dipeptidyl peptidase-4 inhibitors) between 1 January 2013 and 31 December 2021
The clinical concern is the pharmacodynamic clash, not a metabolic one
It is widely distributed throughout the body, being expressed on vascular endothelial cells, T lymphocytes, the gastrointestinal tract, hepatobiliary system, kidneys, and pulmonary tract (61, 62)
Our previous studies showed that activation of p38 protected the heart against I/R injury [52]
US$ 24.59
US$ 23.17
US$ 21.88
US$ 27.50
US$ 25.05
